Genetically guided prescribing: Hope or hype?

Acta Neuropsychiatrica

Volumn 20, Issue 1, 2008, Pages 50-51

  Singh, Ajeet ^a,b   Berk, Michael ^a,b,c,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Geelong Clinic   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d ORYGEN RESEARCH CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASING FACTOR; CYTOCHROME P450; DOPAMINE; GLUTAMIC ACID; MELATONIN; MULTIDRUG RESISTANCE PROTEIN 1; NORADRENALIN; SEROTONIN; SUBSTANCE P;

ARTICLE; CEREBROSPINAL FLUID; DEPRESSION; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; PHARMACOGENOMICS; PRESCRIPTION; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

EID: 38549108922     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2007.00267.x     Document Type: Article

References (17)

1. Lee M. The pharmacogenetics of antidepressant treatments for depressive disorders. Drug Dev Res 2005 65 : 170 178.
2. Mulrow CD, Williams JW, Chiquette E et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med 2000 108 : 154 164.
3. De Leon J, Armstrong S, Cozza K. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006 47 : 75 85.
4. Perlis RH. Cytochrom P450 genotyping and antidepressants. BMJ 2007 334 : 759.
5. Lee MS. Could pharmacogenetics play a role as predictor in treatment of depressive disorders? World J Biol Psychiatry 2007 8 : 2 3.
6. Thompson CA. Too soon to judge value of pharmacogenetic testing in selecting antidepressant. Am J Health Syst Pharm 2007 64 : 453.
7. Richelson E. Pharmacology of antidepressants. Mayo Clinic Proc 2001 76 : 511 527.
8. Poolsup N, Po A, Knight T. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Therapy 2000 25 : 197 220.
9. Doris A, Ebmeier K, Shajahan P. Depressive illness. Lancet 1999 354 : 1369 1375.
10. Nierenberg A. Prediction of response to antidepressants: general principals and clinical implications. Psychiatric Clin N Am 2003 26 : 345 352.
11. Lee MS. Could pharmacogenetics play a role as predictor in treatment of depressive disorders? World J Biol Psych 2007 8 : 2 3.
12. Hung C, Tai J, Lin C et al. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 2005 6 : 411 417.
13. Eichelbaum M, Fromm M, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004 26 : 180 185.
14. Yoshida K, Takahashi H, Higuchi H et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004 161 : 1575 1580.
15. Kim H, Lim S, Kim S et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late life depression. JAMA 2006 296 : 1609 1618.
16. Caspi A, Sugden K, Moffitt T et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003 301 : 386 389.
17. Marcus R, Munafò A, Taane G et al. Neuroticism mediates the association of the serotonin transporter gene with lifetime major depression. Neuropsychobiology 2006 53 : 1 8.